Related Experiment Video
Updated: Jun 29, 2025
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Potential Alzheimer's disease drug targets identified through microglial biology research
Izabela Lepiarz-Raba1, Taufik Hidayat1, Anthony J Hannan2
1Laboratory for Translational Research in Exposures and Neuropsychiatric Disorders (TREND), Braincity: Center of Excellence for Neural Plasticity and Brain Disorders, Nencki Institute of Experimental Biology, Warsaw, Poland.
Introduction:
Microglia, the primary immune cells in the brain, play multifaceted roles in Alzheimer's disease (AD). Microglia can potentially mitigate the pathological progression of AD by clearing amyloid beta (Aβ) deposits in the brain and through neurotrophic support. In contrast, disproportionate activation of microglial pro-inflammatory pathways, as well as excessive elimination of healthy synapses, can exacerbate neurodegeneration in AD. The challenge, therefore, lies in discerning the precise regulation of the contrasting microglial properties to harness their therapeutic potential in AD.
Areas Covered:
This review examines the evidence relevant to the disease-modifying effects of microglial manipulators in AD preclinical models. The deleterious pro-inflammatory effects of microglia in AD can be ameliorated via direct suppression or indirectly through metabolic manipulation, epigenetic targeting, and modulation of the gut-brain axis. Furthermore, microglial clearance of Aβ deposits in AD can be enhanced via strategically targeting microglial membrane receptors, lysosomal functions, and metabolism.
Expert Opinion:
Given the intricate and diverse nature of microglial responses throughout the course of AD, therapeutic interventions directed at microglia warrant a tactical approach. This could entail employing therapeutic regimens, which concomitantly suppress pro-inflammatory microglial responses while selectively enhancing Aβ phagocytosis.
Insights
Microglia play dual roles in Alzheimer's disease (AD), potentially clearing amyloid beta (Aβ) but also driving inflammation. Targeting these immune cells offers a promising therapeutic strategy for AD.
Area of Science:
- Neuroscience
- Immunology
- Neurodegenerative Diseases
Background:
- Microglia, the brain's immune cells, have complex roles in Alzheimer's disease (AD).
- They can be protective by clearing amyloid beta (Aβ) or detrimental by promoting neuroinflammation and synapse loss.
- Precisely regulating microglial functions is key to harnessing their therapeutic potential in AD.
Purpose of the Study:
- To review evidence on microglial manipulation for disease modification in AD preclinical models.
- To explore strategies for ameliorating detrimental microglial effects and enhancing beneficial functions.
Main Methods:
- Examination of preclinical AD models.
- Analysis of therapeutic interventions targeting microglial pathways.
Main Results:
- Microglial pro-inflammatory effects can be suppressed through direct inhibition, metabolic manipulation, epigenetic targeting, and gut-brain axis modulation.
- Amyloid beta (Aβ) clearance by microglia can be enhanced by targeting membrane receptors, lysosomal function, and metabolism.
Conclusions:
- Therapeutic strategies for AD should adopt a tactical approach to microglial modulation.
- Combined approaches that suppress inflammation while enhancing Aβ phagocytosis are promising.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment